Aravive (STU:VE11) Total Liabilities : €10.63 Mil (As of Sep. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Aravive Total Liabilities?

Aravive's Total Liabilities for the quarter that ended in Sep. 2023 was €10.63 Mil.

Aravive's quarterly Total Liabilities declined from Mar. 2023 (€76.27 Mil) to Jun. 2023 (€42.05 Mil) and declined from Jun. 2023 (€42.05 Mil) to Sep. 2023 (€10.63 Mil).

Aravive's annual Total Liabilities increased from Dec. 2020 (€16.16 Mil) to Dec. 2021 (€22.63 Mil) and increased from Dec. 2021 (€22.63 Mil) to Dec. 2022 (€48.61 Mil).

Aravive Total Liabilities Historical Data

The historical data trend for Aravive's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aravive Total Liabilities Chart

Aravive Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Liabilities

Get a 7-Day Free Trial

8.37

11.77

16.16

22.63

48.61

Aravive Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Total Liabilities	Get a 7-Day Free Trial															27.45	48.61	76.27	42.05	10.63

Aravive Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Aravive's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	20.874	+	(1.777	+	25.375
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0.586	+	0)
	=	48.61

Total Liabilities	=	Total Assets (A: Dec. 2022 )	-	Total Equity (A: Dec. 2022 )
	=	58.672	-	10.06
	=	48.61

Aravive's Total Liabilities for the quarter that ended in Sep. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	9.161	+	(0.287	+	1.185
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	10.63

Total Liabilities	=	Total Assets (Q: Sep. 2023 )	-	Total Equity (Q: Sep. 2023 )
	=	12.227	-	1.594
	=	10.63

Aravive Total Liabilities Related Terms

Thank you for viewing the detailed overview of Aravive's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Aravive (STU:VE11) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aravive Inc (STU:VE11) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

ARAV:USA VE11:Germany

Address

3730 Kirby Drive, River Oaks Tower, Suite 1200, Houston, TX, USA, 77098

Website

https://www.aravive.com

Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.

Aravive (STU:VE11) Headlines

No Headlines